Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study.
A group of 13 patients with acute myeloid leukaemia of differing disease status were treated with continuous intravenous infusion of high-dose recombinant interleukin-2 (rIL-2). There was up-regulation of the cellular cytotoxic functions in all these patients following the rIL-2 therapy, with increase in the natural killer (NK) activity, lectin-dependent cellular cytotoxicity, induction of cytotoxicity-linked cytoplasmic serine esterase and lymphocyte activation. However, the clinical response to rIL-2 in these patients was disappointing, especially in patients treated in frank relapse. Although 1 patient treated in early second relapse achieved a third complete remission, the duration of the remission was brief and lasted only 6 months. Adverse reactions among these patients were common. Whether or not lymphokine-activated killer cells are needed to improve the response rate over rIL-2 alone in these patients deserves further investigation.
Lim
S H
SH
Department of Haematology, University College Hospital, London, UK.
Newland
A C
AC
Kelsey
S
S
Bell
A
A
Offerman
E
E
Rist
C
C
Gozzard
D
D
Bareford
D
D
Smith
M P
MP
Goldstone
A H
AH
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D005334:Fever / Q000209:etiology; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D007008:Hypokalemia / Q000209:etiology; D007022:Hypotension / Q000209:etiology; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage; D012074:Remission Induction
D000970:Antineoplastic Agents; D007376:Interleukin-2; D011994:Recombinant Proteins